- Details
- Anticholinergic medications have long been mainstays of overactive bladder (OAB) treatment. Oxybutynin, a first-generation anticholinergic, still accounts for more than half of all OAB medication prescriptions, despite associations with impaired memory and cognition, as well as mounting evidence that it may increase the risk of incident dementia. Biographies: Michael Chancellor, MD, Corewell Healt...
|
- Details
- In this discussion, Diane Newman, talks with Howard Goldman about advances in neuromodulation technology for patients with lower urinary tract dysfunction, overactive bladder, and urinary incontinence. Dr. Goldman highlights the potential of implantable tibial nerve stimulation devices, particularly a small device developed by BlueWind Medical. The device, placed next to the tibial nerve, is power...
|
- Details
- Diane Newman engages in a discussion with Howard Goldman on the Uromonitor, a non-invasive urodynamic device designed to measure bladder pressures in a more comfortable, natural setting. This innovative device, developed in partnership with Bright Urology and the Cleveland Clinic, is placed in the bladder and allows patients to move freely without external catheters. The Uromonitor, with its "Holt...
|
- Details
- Ken Peters joins Diane Newman to present the results of a Phase 2a trial evaluating the safety and efficacy of URO-902, an investigational gene therapy for overactive bladder. URO-902 is a plasma vector that expresses the alpha subunit of the human BK channel, which reduces bladder overactivity and leads to detrusor relaxation. The trial included women between 40 and 70 years old with urgency freq...
|
- Details
- Patient perception of meaningful reductions in bothersome symptoms of overactive bladder (OAB) is lacking. In the phase 3 EMPOWUR trial, vibegron significantly reduced the average daily number of micturitions, urgency episodes, and urge urinary incontinence (UUI) episodes vs placebo. This analysis assessed the meaningfulness of reductions in clinical endpoints observed in EMPOWUR using the patient...
|
- Details
- Joining Diane Newman is Paul Yoo to discuss his presentation from this year's SUFU annual meeting on saphenous nerve stimulation. In this particular study, Dr. Yoo's lab was interested in the mechanistic pathway through which saphenous nerve stimulation can modulate bladder function, and how this could be translated to patients with overactive bladder. Biographies: Paul Yoo, Ph.D., PEng, Associate...
|
- Details
- Diane Newman is joined by Anne Agur to share how they collect data to develop novel models of the human saphenous nerve. These novel models of the human saphenous nerve will be used to develop neuromodulation therapy approaches, both an engineering finite element approach, and for clinicians to look at electrode placement. The 3D data provides a very precise in situ map of the distribution of the...
|
- Details
- Diane Newman is joined by Michael Weber discussing a novel medication for the treatment of overactive bladder and a study Dr Weber presented at the AUA 2021 Annual Meeting. Vibegron, a beta-3 receptor agonist is used for the treatment of overactive bladder. Adults with overactive bladder in the age range, 40 to 75, were randomized to treatment either with Vibegron 75 milligrams per day or placebo....
|
- Details
- In this informational video presentation, Stephen Kraus provides an update on the SUFU overactive bladder (OAB) Clinical Care Pathway as a dissemination effort to broadcast the advantages of the pathway for both physicians and patients. This initiative offers a comprehensive and evidence-based approach to the management of overactive bladder focused for the healthcare provider. After trial and err...
|
- Details
- Joining Diane Newman on UroToday's Bladder Health Center of Excellence is Scott MacDiarmid to discuss the United States Federal Drug Administration (FDA) approval of beta-3 agonist, GEMTESA® (vibegron), for the treatment of overactive bladder (OAB). This approval marks the first new oral branded OAB medication approved by the FDA since 2012. Biographies: Scott A. MacDiarmid, MD is director of the...
|
